Library · Brain & nerves · Alzheimer's disease treatment
Donanemab
Kisunla, donanemab-azbt
Humanized IgG1 monoclonal antibody approved in July 2024 for early Alzheimer’s disease with confirmed amyloid buildup. Targets a toxic form of amyloid beta in plaques; trials showed 35% slower decline over 18 months and an 84% drop in plaque levels, and treatment can stop once amyloid is sufficiently cleared.
Research score 88/100. Reference only, not a dose.
Boxed warning: ARIA - risk of brain swelling and bleeding. MRI monitoring required
- Amyloid Clearance
- Cognitive Protection
- US status
- Prescription Only
- Approval
- FDA Approved (2024)
- Evidence
- Slowed decline by 35% over 18 months. Reduced amyloid plaques by 84% vs baseline
- Research score
- 88 / 100
- Indication
- Early Alzheimer's disease
- Origin
- United States
- Source category
- Brain & Nervous System
- Status group
- Approved / prescription
Mechanism
Binds insoluble, N-truncated pyroglutamate amyloid-beta in brain plaques, clearing them from the brain.
Safety file
Boxed warning for ARIA (brain swelling or bleeding from amyloid clearance); three trial deaths were linked to ARIA.
- ARIA (brain swelling/bleeding)
- Infusion reactions